News for 'Consumer Healthcare'

Tier-II, -III mkts make 62% of new health insurance policies

Tier-II, -III mkts make 62% of new health insurance policies

Rediff.com12 Dec 2025

Tier-II, Tier-III, and rural regions accounted for 62 per cent of all new health insurance policies sold by insurers so far in 2025-26 (FY26), according to a Policybazaar report. These regions are also witnessing a rise in the sum assured opted by customers.

FPIs resume selling in Nov; withdraw Rs 3,765 cr from equities

FPIs resume selling in Nov; withdraw Rs 3,765 cr from equities

Rediff.com30 Nov 2025

After a brief pause in October, foreign investors resumed selling, pulling out a net Rs 3,765 crore from Indian equities in November, driven by global risk-off sentiment, volatility in global tech stocks and selective preference for primary markets over secondary markets.

WHO issues alert against Indian cough syrups. They are...

WHO issues alert against Indian cough syrups. They are...

Rediff.com14 Oct 2025

The World Health Organisation (WHO) has issued an alert against three "substandard" oral cough syrups identified in India and urged national regulatory authorities worldwide to immediately notify it if these are detected in their country.

Reliance investments in AI infra may top $12-15 bn

Reliance investments in AI infra may top $12-15 bn

Rediff.com26 Oct 2025

Billionaire Mukesh Ambani's Reliance Industries Ltd may spend about $12-15 billion over the next few years on AI infrastructure that could include a giant 1GW data centre, Morgan Stanley said in a report. Ambani had at the company's annual shareholder meeting in August announced a major push into AI through a new subsidiary and strategic partnerships.

AHPI, Star Health in spat over cashless service

AHPI, Star Health in spat over cashless service

Rediff.com15 Sep 2025

If cashless services are suspended, AHPI said, its member hospitals will continue to treat Star Health policyholders, but patients will have to pay upfront and later seek reimbursements directly from the insurer.

When Do You Introduce Spice To A Baby?

When Do You Introduce Spice To A Baby?

Rediff.com18 Nov 2025

You can slowly build up spices over six to nine months by adding ajwain, jeera, coriander, cardamom and cinnamon powders for flavouring different recipes, says Madhavi Bhardwaj.

India, New Zealand conclude FTA negotiations

India, New Zealand conclude FTA negotiations

Rediff.com22 Dec 2025

New Zealand Prime Minister Christopher Luxon on Monday said the negotiations for a free trade agreement with India have been concluded.

Bajaj Finserv targets a 22% profit CAGR, double customers in 5 years

Bajaj Finserv targets a 22% profit CAGR, double customers in 5 years

Rediff.com8 Dec 2025

Bajaj Finserv - the holding company of Bajaj group's financial services business - has laid out plans for the next five years. During this period, it is eyeing 18-22 per cent compound annual growth rate (CAGR) in net profit at Rs 21,000-24,000 crore on a consolidated basis.

Sarvam AI To Launch India's First LLM In Feb

Sarvam AI To Launch India's First LLM In Feb

Rediff.com20 Nov 2025

Sarvam's LLM will have more than 17 trillion tokens with 17 to 20 per cent coming from Indian data

No deaths due to codeine syrup, accused linked to SP: Yogi

No deaths due to codeine syrup, accused linked to SP: Yogi

Rediff.com22 Dec 2025

Uttar Pradesh Chief Minister Yogi Adityanath on Monday strongly rebutted allegations by Leader of Opposition Mata Prasad Pandey over 'deaths' allegedly due to the consumption of fake medicines and codeine syrup, asserting in the Assembly that no such case has come to the notice of the state government so far.

'Govt Has Executed A Commendable Task'

'Govt Has Executed A Commendable Task'

Rediff.com5 Dec 2025

'...not merely in managing fiscal mathematics, but in demonstrating conservatism and prudence within that framework.' 'Looking forward, we believe sufficient growth drivers exist -- ranging from government reforms to revival in consumption to favourable monsoons. Numerous factors support the Indian economy.'

Core acquisition adds to Metropolis Healthcare's long-term growth plans

Core acquisition adds to Metropolis Healthcare's long-term growth plans

Rediff.com27 Dec 2024

Metropolis Healthcare (MHL) has decided to acquire a 100 per cent stake in Gurgaon-based Core Diagnostics for Rs 247 crore. This is about 2.2x FY24 (financial year 2023-24) enterprise value (EV)/sales and estimated 14x FY26 EV/Ebitda for the deal.

No cashless treatment for Bajaj Allianz customers of north India

No cashless treatment for Bajaj Allianz customers of north India

Rediff.com22 Aug 2025

The Association of Healthcare Providers - India (AHPI), representing hospitals and healthcare institutions across the country, has advised its members in north India to stop providing cashless treatment facilities for policyholders of Bajaj Allianz General Insurance Company, with effect from September 1.

Want To Invest In US Markets? Read This

Want To Invest In US Markets? Read This

Rediff.com24 Nov 2025

New investors or those with lower-than-planned exposure should add US-oriented funds through SIPs.

Wipro Q2 profit inches up; launches 'Wipro Intelligence' to boost AI push

Wipro Q2 profit inches up; launches 'Wipro Intelligence' to boost AI push

Rediff.com16 Oct 2025

IT services firm Wipro on Thursday reported a marginal increase in consolidated net profit to Rs 3,246.2 crore in the July-September quarter, even as company CEO and MD Srini Pallia asserted that the demand environment remains robust with discretionary spends shifting towards AI-related projects.

iPhone Affordability Index Reveals: Most Indians Can't...

iPhone Affordability Index Reveals: Most Indians Can't...

Rediff.com16 Sep 2025

The average Indian worker must labour for an extraordinary 160 full working days to afford Apple's latest iPhone 17 Pro.

How GST Rate Cut Will Impact Sectors

How GST Rate Cut Will Impact Sectors

Rediff.com8 Sep 2025

Lower rates effectively increase disposable income, strengthen purchasing capacity, and support broader consumption growth.

'No Such Thing As Diabetes Reversal'

'No Such Thing As Diabetes Reversal'

Rediff.com14 Nov 2025

'In diabetes remission, you go below a 6.5 HbA1c without medication.' 'And this happens only when you lose 10 to 15 per cent of your body weight with a good amount of lifestyle and dietary changes, exercise and sometimes medication.' 'You have to be able to sustain your HBA1C below 6.5 for at least a year without medication to say that the patient is in remission.'

Amazon enters India's $15 bn diagnostics market with At-Home testing

Amazon enters India's $15 bn diagnostics market with At-Home testing

Rediff.com23 Jun 2025

Amazon India has launched Amazon Diagnostics, an at-home healthcare service that allows customers to book lab tests, schedule appointments and receive digital reports directly via the Amazon app. Initially available in six cities-Bengaluru, Delhi, Gurgaon, Noida, Mumbai and Hyderabad-the service covers more than 450 PIN codes and offers access to over 800 diagnostic tests.

Cashless Facility On Hold? How To Manage

Cashless Facility On Hold? How To Manage

Rediff.com15 Oct 2025

To handle the sudden loss of cashless facility, patients should maintain an emergency fund or a short-term credit line to manage all or part of hospitalisation costs.

GST 2.0: These will get cheaper from September 22

GST 2.0: These will get cheaper from September 22

Rediff.com4 Sep 2025

Some of the key names include: Maruti, M&M, Ashok Leyland, Britannia, Ultratech, JK Cement, Havells, Voltas, Amber, Metro, Trent, LemonTree, Indian Hotels, Niva Bupa, HDFC Life, IGL, Acme Solar, Suzlon, Swiggy, Delhivery, ICICI Bank, HDFC Bank, Bajaj Finance, Shriram Finance," according to a report by Motilal Oswal Financial Services.

Ditch Quick-Money Lures This Diwali!

Ditch Quick-Money Lures This Diwali!

Rediff.com20 Oct 2025

: Build lasting wealth via disciplined, long-term mutual fund investing in India's compounding marathon, Shanaihi, Shanaihi, says Ramalingam Kalirajan

Stocks of domestic-facing firms lag despite tariff-related hedge calls

Stocks of domestic-facing firms lag despite tariff-related hedge calls

Rediff.com1 Sep 2025

To shield against US President Donald Trump's tariff shock, analysts have been advising investors to focus on stocks of domestic-oriented companies, rather than export-centric ones, to minimise potential losses.

Smallcaps Face Their Toughest Samvat Yet

Smallcaps Face Their Toughest Samvat Yet

Rediff.com18 Oct 2025

'Defence, capital goods, engineering, capital market-related stocks, autos, and cement sectors are my bullish bets for Samvat 2082.'

IPL's Valuation Hits Flat Pitch

IPL's Valuation Hits Flat Pitch

Rediff.com16 Oct 2025

The IPL's overall valuation fell by 8 per cent to Rs 76,100 crore in 2025.

'Next Samvat Could See Equities Align With Economic Growth'

'Next Samvat Could See Equities Align With Economic Growth'

Rediff.com16 Oct 2025

'The outlook for the next Samvat is more constructive, as many of the earlier drags are gradually becoming supports.'

Small is big for PEs, companies as M&As rise to $45.4 billion in H1

Small is big for PEs, companies as M&As rise to $45.4 billion in H1

Rediff.com11 Jul 2025

India's mergers & acquisitions (M&As) market recorded deals worth $45.44 billion in the first half of 2025, up nearly 3.3 per cent from a year ago, even as ultra large-ticket transactions remained subdued. During the first half, the 7.1 per cent rise in deal count to 1,614 signals continuing appetite among domestic conglomerates and private equity (PE) funds for mid-sized and smaller assets.

Trump's 100% tariff on pharma unlikely to hurt domestic industry: Experts

Trump's 100% tariff on pharma unlikely to hurt domestic industry: Experts

Rediff.com26 Sep 2025

Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.

Vaishnaw presents first made-in-India chip to Modi at Semicon 2025

Vaishnaw presents first made-in-India chip to Modi at Semicon 2025

Rediff.com2 Sep 2025

Modi inaugurated the Semicon India 2025 in Delhi, in the presence of Chief Minister Rekha Gupta, and Union Minister of Commerce and Industry Jitin Prasada.

CBSE's 'sugar boards' in schools aim to curb childhood obesity

CBSE's 'sugar boards' in schools aim to curb childhood obesity

Rediff.com25 May 2025

The Central Board of Secondary Education (CBSE) has directed schools to set up dedicated 'Sugar Boards' to raise awareness about sugar consumption and combat childhood obesity. Experts hail the initiative as a significant step towards promoting healthier dietary habits among students and families. The boards will display information on the sugar content in common snacks, drinks, and meals, helping children make informed choices. This move comes as data reveals alarmingly high sugar intake among Indian children, exceeding the World Health Organization's recommended limits.

Pharma cos may see short-term price blip: Ind-Ra

Pharma cos may see short-term price blip: Ind-Ra

Rediff.com27 Aug 2025

Any potential tariffs on pharmaceutical imports into the US are unlikely to impact the credit profiles of Indian firms except for a short-term pricing blip, according to a report by India Ratings and Research (Ind-Ra). The report stated that the US generics market contributes around 35 per cent to the total revenue of the leading Indian pharma firms.

Wipro Profits Up 10.9%

Wipro Profits Up 10.9%

Rediff.com18 Jul 2025

'We remain cautious in this environment, and the uncertainty continues.'

Top Competitive Exams After Class 12

Top Competitive Exams After Class 12

Rediff.com18 Aug 2025

rediffGURU Nayagam PP, career counsellor and the founder of EduJob360, counsels students and aspiring professionals about how they can make the right career decision.

Sensex rises 317 pts on gains in auto, pharma shares

Sensex rises 317 pts on gains in auto, pharma shares

Rediff.com15 Jul 2025

Stock markets snapped the four-day falling streak on Tuesday with the benchmark Sensex rebounding by 317 points on buying in auto and pharma shares amid a decline in retail inflation to a more than six-year low, nearing the RBI's comfort zone. The 30-share BSE Sensex climbed 317.45 points or 0.39 per cent to settle at 82,570.91. During the day, it jumped 490.16 points or 0.59 per cent to 82,743.62. The 50-share NSE Nifty edged higher by 113.50 points or 0.45 per cent to 25,195.80.

10 Monsoon Healthcare Tips

10 Monsoon Healthcare Tips

Rediff.com21 Jul 2023

Including foods rich in Vitamin C, such as citrus fruits, berries, kiwi, and leafy greens, can help meet the recommended daily intake, suggests Dr Prasad Kuvalekar.

Markets fall on selling in IT shares, foreign fund outflows

Markets fall on selling in IT shares, foreign fund outflows

Rediff.com14 Jul 2025

Benchmark stock indices Sensex and Nifty declined on Monday, extending the losing run to the fourth day amid selling in IT shares and foreign fund outflows. The 30-share BSE Sensex dropped by 247.01 points or 0.30 per cent to settle at 82,253.46. During the day, it fell 490.09 points or 0.59 per cent to 82,010.38 but recovered some of the losses towards the close.

GlaxoSmithkline Consumer FY-02 results on Jan 31

GlaxoSmithkline Consumer FY-02 results on Jan 31

Rediff.com15 Jan 2003

A meeting of the board of directors of GlaxoSmithkline Consumer Healthcare Ltd is scheduled on January 31, 2003, inter alia, to consider and adopt the audited financial results for the year ended December 31, 2002.\n\n\n\n

'India one of the attractive markets for AI-led solutions'

'India one of the attractive markets for AI-led solutions'

Rediff.com16 Apr 2025

'The country is a good test bed for enterprise adoption, but to scale rapidly, companies will need to look outside the country for customers.'

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

Rediff.com12 Aug 2025

If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.

'Our Nifty Target For December Is 26,500'

'Our Nifty Target For December Is 26,500'

Rediff.com24 Jun 2025

'We continue to view India as a standout within EM.'